News

Applied Clinical Trials Online3d
Phase III MATTERHORN Trial Shows Imfinzi Combo Significantly Improves Event-Free Survival in Resectable Gastric and GEJ Cancers
Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...
Pharmaceutical Technology4d
ASCO25: Genmab’s Rina-S en route to ‘blockbuster potential’ amid further positive data
The ADC market was valued at $8.6bn in 2023, with it forecast to exceed $45bn by 2030, according to analysis by GlobalData.
SecuringIndustry.com4d
WHO warns again of falsified cancer drug Imfinzi
Three more fake batches of the cancer immunotherapy have been encountered in Iran and Türkiye, warns the agency.
SurvivorNet on MSN5d
Adding Immunotherapy To The Treatment Plan Helps Keep Gastric Cancer Under Control Longer: Breaking Down The Practice-Changing New Data
Data shows adding durvalumab (Imfinzi) to the standard chemotherapy combination known as FLOT before and after surgery kept ...
Notable healthcare headlines for the week: AstraZeneca, Eli Lilly, Bristol Myers in focus
Asad Haider, head of the healthcare business unit within Goldman Sachs Research, now forecasts the market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, to ...